The Netherlands Cancer Institute: all 230 studies

Page 2 of 3. Open to participants first (66), then studies with results posted, then the rest; newest registration first within each.

• Propranolol in AngiosarcomaCompletedNCT04518124Phase 2
• Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue SarcomasActive, not recruitingNCT04425967Not applicable
• Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedNCT04330430Phase 2
• Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialCompletedNCT04307329Phase 2
• Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentTerminatedNCT04287894Phase 1
• Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2
• Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal CancerStatus unknownNCT04231175Not applicable
• Improving the Safety of Fluoropyrimidine-based ChemotherapyStatus unknownNCT04194957Not applicable
• Diagnostic Yield of Colonoscopy Surveillance in Testicular Cancer Survivors Treated With Platinum-based ChemotherapyCompletedNCT04180033Not applicable
• ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCompletedNCT04148066Not applicable
• Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2
• The SONImage StudyActive, not recruitingNCT04125277Not applicable
• Early Response Evaluation in NSCLC Patients Treated With ImmunotherapyTerminatedNCT04082988Not applicable
• Assessing Health-related Quality of Life in Sarcoma PatientsCompletedNCT04071704
• LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)WithdrawnNCT04031872Phase 1/2
• Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Active, not recruitingNCT04017455Phase 2
• Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung MetastasisTerminatedNCT03984019Not applicable
• Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck CancerActive, not recruitingNCT03968679Not applicable
• Internet-based WOrk-related Cognitive Rehabilitation for Cancer Survivors: a Randomized Controlled TrialStatus unknownNCT03900806Not applicable
• Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2
• Technetium Based Radioguided Surgery for Prostate Cancer (TRACE) StudyStatus unknownNCT03857113
• Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve FertilityTerminatedNCT03852979Phase 2
• Health After eaRly Menopause Due to OophorectomyStatus unknownNCT03835793
• The Impact of a Web-based Patient Decision Aid for Women Considering Breast ReconstructionCompletedNCT03791138Not applicable
• T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
• Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Active, not recruitingNCT03772028Phase 3
• Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerCompletedNCT03727724Phase 2
• PEnile Cancer Radio- and Immunotherapy CLinical Exploration StudyCompletedNCT03686332Phase 2
• 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCCompletedNCT03564197Not applicable
• ctDNA as a Biomarker for Treatment Response in HNSCCCompletedNCT03540563Not applicable
• Vinorelbine in Advanced BRAF-like Colon CancerCompletedNCT03482362Phase 2
• Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerWithdrawnNCT03470350Phase 1/2
• Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)Active, not recruitingNCT03448835Phase 2
• Clinical Impact of Dedicated MR Staging of Ovarian CancerStatus unknownNCT03399344Not applicable
• Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain TumorsTerminatedNCT03394716
• Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1
• Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapyCompletedNCT03376386Not applicable
• Dose-Effect Relation of Salivary Gland IrradiationCompletedNCT03367780
• Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.Active, not recruitingNCT03348150Phase 3
• Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCStatus unknownNCT03341845Phase 2
• The Effectiveness of Patient Navigation in Cancer CareStatus unknownNCT03305965Not applicable
• Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen AblationCompletedNCT03297385Phase 2
• Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelCompletedNCT03295565Phase 2/3
• To Decrease Fatigue With Light TherapyCompletedNCT03242902Phase 3
• Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223CompletedNCT03223727
• Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223CompletedNCT03223597
• AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerTerminatedNCT03147040Phase 2
• Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2
• Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate CancerTerminatedNCT03066154Phase 1
• Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2
• ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaCompletedNCT03003637Phase 1/2
• Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2
• Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLCWithdrawnNCT02947113Phase 2
• Preoperative Breast IrradiationTerminatedNCT02941835Not applicable
• Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)CompletedNCT02938273Phase 1
• The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast CancerCompletedNCT02934126
• Multicentric Randomised Trial for Resectable Gastric CancerActive, not recruitingNCT02931890Phase 2
• Carboplatin-cyclophosphamide Combined With AtezolizumabCompletedNCT02914470Phase 1
• Pre- Versus Postoperative Accelerated Partial Breast IrradiationTerminatedNCT02913729Not applicable
• Lung Cancer Early Molecular Assessment TrialStatus unknownNCT02894853
• HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced MelanomaCompletedNCT02836548Phase 1/2
• A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsTerminatedNCT02826512Phase 2
• Study With Improved Solubility PazopanibCompletedNCT02810756Early Phase 1
• Substantially Improving the Cure Rate of High-risk BRCA1-like Breast CancerActive, not recruitingNCT02810743Phase 3
• Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaTerminatedNCT02775006Phase 3
• Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood SpotsCompletedNCT02768441Early Phase 1
• Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung CancerStatus unknownNCT02743923Phase 3
• Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase ActivityCompletedNCT02718664Not applicable
• Molecular Stool Testing for Colorectal Cancer SurveillanceCompletedNCT02715141
• Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary OriginStatus unknownNCT02695459Phase 2
• Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric SymptomsCompletedNCT02672189Phase 3
• Study With T-cel Receptor Gene Therapy in Metastatic MelanomaStatus unknownNCT02654821Phase 1/2
• Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma PatientsStatus unknownNCT02625337Phase 2
• Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma PatientsTerminatedNCT02575066Phase 2
• Mapping of Sentinel Lymph Node Drainage Using SPECT (SUSPECT) (SUSPECT)CompletedNCT02572661Not applicable
• Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) PatientsActive, not recruitingNCT02499367Phase 2
• Nivolumab in Patients With Recurrent Malignant MesotheliomaCompletedNCT02497508Phase 2
• Management of Low-risk (Grade I and II) DCISActive, not recruitingNCT02492607Not applicable
• Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLCCompletedNCT02492568Phase 2
• Identifying Subgroups With High Cardiovascular Risk in Breast Cancer SurvivorsStatus unknownNCT02485626
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
• Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsActive, not recruitingNCT02437279Phase 1
• 4D FDG PET in Esophageal CancerCompletedNCT02424864Not applicable
• Comparing Two Palliative Schemes of Radiotherapy for Head and Neck CancerTerminatedNCT02421458Not applicable
• Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced CancerCompletedNCT02418624Phase 1
• Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of FluoropyrimidinesCompletedNCT02324452Not applicable
• PET Response During Chemoradiation of Lung CancerCompletedNCT02315053Not applicable
• Prospective Pilot Study ANDPreciseStatus unknownNCT02292407Phase 3
• Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside TamoxifenCompletedNCT02285179Phase 1/2
• Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3
• An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income CountriesStatus unknownNCT02247713
• Lapatinib Plus Trametinib in KRAS Mutant NSCLCCompletedNCT02230553Phase 1/2
• Olaparib and Radiotherapy in Head and Neck CancerActive, not recruitingNCT02229656Phase 1
• Olaparib and Radiotherapy in Inoperable Breast CancerCompletedNCT02227082Phase 1
• Organ Motion and Early Tumor Response MeasurementCompletedNCT02139488
• Dose Reduction of Preoperative Radiotherapy in Myxoid LiposarcomasStatus unknownNCT02106312Phase 2
• RCT of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast CancerCompletedNCT02091765Phase 3
• Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompletedNCT02039336Phase 1/2
• Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2Active, not recruitingNCT01996267Phase 3
• Combined Modality Treatment of Sarcomas of the ExtremitiesCompletedNCT01985295Phase 1

← The Netherlands Cancer Institute overview and focus areas